louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05892250: Dynamic Humeral Centering Exercises in Subacromial Pain Syndrome
Official title: Effects of Dynamic Humeral Centering Exercises on Functionality and Disability in Subacromial Pain Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Shoulder Pain
Shoulder Impingement Syndrome
Lead sponsor: Universidad de Antofagasta
Sponsor class: OTHER
First posted: 2023-06-07
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Subacromial pain syndrome is one of the most common musculoskeletal health conditions, causing decreased of range of motion, loss of muscle strength and disability in the shoulder region. It has been proposed that dynamic humeral centering exercises could contribute to overcome these disorders, through the modification of the dimensions of the subacromial space, however, there is no consensus on its effectiveness nor direct variables that account for its efficacy. Therefore, the aim of this research is to determine the effects of a dynamic humeral centering exercise program on the functionality and disability of patients with subacromial pain syndrome.The effects of the dynamic humeral head exercises program, as well as the objective description of factors and variables associated with subacromial pain syndrome, will also allow rehabilitation science professionals to aim their interventions according to the knowledge of direct variables, which will allow objective follow-up of interventions on subacromial pain syndrome diagnosed patients.


Eligibility criteria: Inclusion Criteria:

* Older than 18 years old and less than 60 years old.
* Pain in the lateral and upper arm region for more than two weeks of evolution.
* At least three positive tests in the following: Neer's impingement sign, Hawkins-Kennedy impingement sign, Pattes' maneuver, Jobe's test or painful arch.

Exclusion Criteria:

* Having any of the following diagnoses: frozen shoulder, shoulder girdle joint instability, cancer, glenohumeral arthrosis, symptomatic acromioclavicular arthritis, glenohumeral arthritis, rheumatoid arthritis, or fibromyalgia.
* Cervical or thoracic pain.
* Fracture or surgery in the shoulder region or in the last 6 months.

Primary outcomes:
measure: Subacromial space dimensions
timeFrame: baseline
Secondary outcomes:
measure: Pain intensity
timeFrame: baseline
measure: Range of motion
timeFrame: baseline
measure: Muscular endurance
timeFrame: baseline
measure: Muscular endurance
timeFrame: baseline
measure: Shoulder Pain and Disability Index
timeFrame: baseline
Other outcomes:
Locations:
city: Antofagasta
country: Chile
facility: Universidad de Antofagasta
Study officials:
References:
Clinical trial NCT04360850: Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic
Official title: Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Online Therapy
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 818
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adult clinical psychologists

Brief summary: A brief online survey to be completed by clinical therapists.

Detailed description: A brief online survey to be completed by clinical therapists. This brief 28 question online survey asks mental health care providers questions about their use of technology.

Eligibility criteria: Inclusion Criteria:

• Must be 18 years old, and must be a licensed mental healthcare provider actively treating patients within the past year.

Exclusion Criteria:

• Less than 18 years old, or if you are not a licensed mental healthcare provider actively treating patients within the past year.

Primary outcomes:
measure: responses to the survey questions
timeFrame: measured at the time they take the survey, data collection will continue for up to 1 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
affiliation: University of Washington
name: Hunter Hoffman, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sampaio M, Navarro Haro MV, Wilks C, De Sousa B, Garcia-Palacios A, Hoffman HG. Spanish-Speaking Therapists Increasingly Switch to Telepsychology During COVID-19: Networked Virtual Reality May Be Next. Telemed J E Health. 2021 Aug;27(8):919-928. doi: 10.1089/tmj.2021.0124. Epub 2021 Jun 28.
citation: Sampaio M, Haro MVN, De Sousa B, Melo WV, Hoffman HG. Therapists Make the Switch to Telepsychology to Safely Continue Treating Their Patients During the COVID-19 Pandemic. Virtual Reality Telepsychology May Be Next. Front Virtual Real. 2021 Jan;1:576421. doi: 10.3389/frvir.2020.576421. Epub 2021 Jan 15.
Clinical trial NCT02152423: Enoxamed Study in the Treatment of Acute Coronary Syndromes
Official title: Comparison of the Anti Xa Activity in the Enoxaparin for Acute Coronary Syndromes Admitted to the Emergency. Randomized Clinical Trial ENOXAMED Versus LOVENOX
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Coronary Syndrome
Keywords: enoxaparin
Enoxamed
lovenox
anti Xa
acute coronary syndrome
Lead sponsor: University of Monastir
Sponsor class: OTHER
Collaborators: name: University Hospital Fattouma Bourguiba
First posted: 2014-06-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Because of their anti-Xa and ease of administration activity, the Low molecular weight heparin represent an attractive alternative to the unfractionated heparin. Several clinical trials have demonstrated that Low molecular weight heparin was more effective than Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the most studied. Its use is recommended.

Demonstrate that Enoxamed® is comparable to that of Lovenox® in the anti-Xa activity action.

Detailed description: Single-center randomized controlled trial, single-blind, including patient with an acute coronary syndrome confirmed, to measure the anti-Xa activity between H0 and H4.the study was done on two groups ; ENOXAMED® group : In this case the patient receives an injection of enoxaparin ( ENOXAMED® ; Unimed Laboratories) intravenously. Curative dose (100 IU/10 kg).

Control group ( LOVENOX ® ) In this case the patient receives LOVENOX intravenous injection curative dose of 100 kg IU/10 .

Eligibility criteria: Inclusion Criteria:

* Age over 18 year old
* With an acute coronary syndrome confirmed

Exclusion Criteria:

* Age less than 18 years
* Persistent ST- segment elevation
* Contre indication of enoxaparin and heparin in general.
* Patient participating in another study,
* Pregnant or nursing women
* patients taking an anticoagulant in the last three months,
* Patients with coagulopathy

Primary outcomes:
measure: anti Xa activity (UI/ml)
timeFrame: at baseline and after 4 hours
Secondary outcomes:
measure: adverse events
timeFrame: during hospital stay with an average of 5 days
Other outcomes:
Locations:
city: Monastir
country: Tunisia
facility: Emergency Department of University Hospital of Monastir
Study officials:
affiliation: University hospital of Monastir
name: Nouira Samir, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03200223: Lifestyle Related Disease Management With Wearable Device and Mobile Application
Official title: A Study of the Management of the Patient's Disease Based on the Life Log Data of Patient With Lifestyle-related Diseases Through a Wearable Device and Mobile App
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Obesity
Life Style Induced Illness
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2017-06-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In order to study the effectiveness of personalized healthcare intervention for lifestyle-related diseases, investigators designed this study using mobile application and clinical feedback coaching.


Eligibility criteria: Inclusion Criteria:

* Study participants must agree to support by him/herself at enroll time
* Patient without severe cardiopulmonary disease, cancer, or other acute diseases
* Patient must be over BMI \> 23 kg/m2

Exclusion Criteria:

* Patient who did not agree with this study
* Patient with severe cardiopulmonary disease, cancer, or other acute diseases
* Patient who are pregnant

Primary outcomes:
measure: Weight change
timeFrame: Baseline and after 2 weeks, 4 weeks of lifestyle modification
Secondary outcomes:
measure: Body composition change
timeFrame: Baseline and after 2 weeks, 4 weeks of lifestyle modification
measure: Laboratory test result change
timeFrame: Baseline and after 2 weeks, 4 weeks of lifestyle modification
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Jeong-Whun Kim, PhD
role: STUDY_CHAIR
References:
citation: Kim JW, Ryu B, Cho S, Heo E, Kim Y, Lee J, Jung SY, Yoo S. Impact of Personal Health Records and Wearables on Health Outcomes and Patient Response: Three-Arm Randomized Controlled Trial. JMIR Mhealth Uhealth. 2019 Jan 4;7(1):e12070. doi: 10.2196/12070.
Clinical trial NCT00593723: IMRT Tomotherapy for Esophagus Cancer
Official title: IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Esophagus Cancer
Keywords: IMRT
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2008-01-15
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Concurrent chemotherapy and radiation therapy are the standard of care for inoperable patients with esophagus cancer. Unfortunately, the 5-year survival of 20% for this population is quite low. Methods to intensify radiation therapy delivery without increasing local toxicities are needed. Intensity modulated radiation therapy (IMRT) is an advanced method of delivering external beam radiation that may minimize the volume of normal tissue irradiated to high dose and thus decrease the risk of normal tissue toxicity. The proposed study will prospectively test whether IMRT is tolerable for delivering IMRT doses of 60 Gy for patients with esophagus cancer.


Eligibility criteria: Inclusion Criteria:

* Age \>= 18
* Karnofsky Performance Status of \>= 60
* TNM Stages T1-4, N0-3, M0
* Pathologic confirmation of esophagus cancer
* Evaluation by medical oncologist determines that the patient is medically fit for concurrent chemotherapy
* Evaluation by surgeon determines that patient is unresectable

Exclusion Criteria:

* Age \< 18
* Karnofsky Performance Status \< 60
* Radiographic or pathologic evidence of distant metastatic disease (classified as M1b in AJCC staging manual)
* Prior radiation therapy to the thorax or upper abdomen, preventing definitive radiation therapy.
* Pregnant or lactating, if female.

Primary outcomes:
measure: The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.
timeFrame: One year after protocol registration
Secondary outcomes:
measure: Evaluate local recurrence rates
timeFrame: Until patient progressive disease or death
measure: Evaluate disease-free survival rates
timeFrame: Until patient progressive disease or death
measure: Evaluate regional recurrence rates
timeFrame: Until patient progressive disease or death
measure: Evaluate distant recurrence rates
timeFrame: Until patient progressive disease or death
measure: Evaluate overall survival rates
timeFrame: Until patient progressive disease or death
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Jeffrey Bradley, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04600323: Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
Official title: Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Metabolic Acidosis
Chronic Kidney Disease
Cognitive Dysfunction
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2020-10-23
Enrollment: 34
Sex: ALL
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a pilot, randomized, double-blinded, placebo-controlled, 12-month trial of 50 patients with CKD stage 3b-4 with metabolic acidosis to examine the effect of sodium bicarbonate therapy on cognitive and cerebrovascular function.


Eligibility criteria: Inclusion Criteria:

* Age 50-75 years old
* Serum bicarbonate 16-22 mEq/L on 2 separate measurements (at least 1 day apart)
* CKD stage 3b or 4 at time of screening (eGFR 15-44 ml/min/1.73m2)
* Blood pressure \<130/80 mm Hg prior to randomization
* Use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker
* Stable anti-hypertensive regimen for at least one month prior to randomization
* Montreal Cognitive Assessment Score \> 24
* No history of stroke
* No history of dementia
* No history of neurologic disease
* Able to provide consent

Exclusion Criteria:• Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year

* Use of chronic daily oral alkali within the last 3 months (including sodium bicarbonate, calcium carbonate or baking soda)
* Uncontrolled hypertension
* Serum potassium \< 3.3 or ≥ 5.5 mEq/L at screening
* New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30%, or hospital admission for heart failure within the past 3 months
* Factors judged to limit adherence to interventions
* Anticipated initiation of dialysis or kidney transplantation within 12 months
* Current participation in another research study
* Pregnancy or planning to become pregnant or currently breastfeeding
* Chronic use of supplemental oxygen

Primary outcomes:
measure: Change in Cognitive Function Composite Score at 12 Months
timeFrame: Baseline and 12 months
measure: Change in Fluid Cognition Composite Score at 12 Months
timeFrame: baseline and 12 months
measure: Change in Crystallized Cognition Composite Score at 12 Months
timeFrame: baseline and 12 months
Secondary outcomes:
measure: Change in Cerebrovascular Reactivity at 12 Months
timeFrame: Baseline and 12 months
measure: Percent Change in Mean Blood Flow Velocity of the Middle Cerebral Artery at 12 Months
timeFrame: Baseline and 12 months
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Anschutz Medical Campus
state: Colorado
Study officials:
References:
Clinical trial NCT05554523: How Does Skin Tone Affect Quantitative Photoacoustic Imaging
Official title: How Does Skin Tone Affect Quantitative Photoacoustic Imaging
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vitiligo
Skin Abnormalities
Lead sponsor: University of Cambridge
Sponsor class: OTHER
Collaborators: name: Cancer Research UK
First posted: 2022-09-26
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Normal adult population across range of skin tones

Brief summary: Photoacoustic imaging (PAI) is an emerging method which combines light and ultrasound to assess the blood content and oxygenation of the body. Light is absorbed by the blood, leading to the generation of ultrasound, from which the levels of oxygen can be derived. This high sensitivity to blood has seen it applied in multiple clinical trials for the assessment of a number of conditions including breast cancer assessment. However, the accuracy of the measurements and image quality is known to decrease as you look deeper into the body because light intensity decreases. Melanin in the skin is known to absorb light very strongly and so there is considerable concern that this may bias measurements made in people with darker skin tones compared to those with lighter skin tones. In this pilot study, we intend to recruit volunteers with a wide range of skin tones and vitiligo. We will scan a number of blood vessels and muscles using PAI and evaluate the photoacoustic measurements of blood content and oxygenation to identify, and ultimately correct for, biases in advance of further clinical studies.


Eligibility criteria: Inclusion Criteria:

1. Voluntary adult non-vulnerable participants between the age of 20 to 70.
2. Can understand the Information sheet and give informed consent in English.
3. Normal or Overweight BMI (18.5 to 29.9)

Exclusion Criteria:

1. No participants who cannot give informed consent.
2. No tattoos or scarring of the regions to be imaged.
3. No pulmonary sleep disorder, or active respiratory disorders that may affect the blood oxygenation levels.

Primary outcomes:
measure: Quantitative photoacoustic imaging
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00281723: Efficacy of Adhesive Tablets in Treating Oral Ulcers (Aphthous)
Official title: Phase 2 Study of Efficacy of Adhesive Tablets in Treating Oral Ulcers (Aphthous)
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: Ulcer, Aphthous
Keywords: Aphthous
oral
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
Collaborators: name: Grant from "Axiomedic. Advanced Medical Solutions", Zurich, Switzerland
First posted: 2006-01-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Recurrent Aphthous Stomatitis (RAS) of the oral mucosa is a common and painful condition. Despite advances in therapeutic means there is still necessary to find a way to alleviate the local pain and discomfort induced by the mucosal ulceration.

The hypothesis was to study the effectiveness and acceptance of a herbal adhesive tablets in the treatment of RAS.

Participants in the study will be examined for oral lesions, will be instructed how to apply the oral-tablet, and will be interviewed during the follow-up period up to one week after the application.


Eligibility criteria: Inclusion Criteria (in healthy individuals):

* Age above 18 years old.
* Non-pregnant women.
* Healthy or controlled chronic diseases.
* Examination at the Oral Medicine Clinic

Inclusion Criteria (in RAS patients):

* Age above 18 years old.
* Non-pregnant women.
* Clinical diagnosis of RAS.
* Examination at the Oral Medicine Clinic

Exclusion Criteria:

* Oral lesion suspected to be malignant.
* Ulcerative oral lesion other than RAS.
* Another experimental oral intervention within the last 24 hours.
* Pregnant women.
* Allergy to components of the Pro-pe adhesive tablet

Primary outcomes:
measure: Serial questionnaires within 1 week post treatment to assess patient's perception, patient's pain relief and local adverse events in comparison to his past experience with other local treatments for oral ulcers.
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization,
Study officials:
affiliation: Hebrew University-Hadassah School of Dental Medicine
name: Rakefet Czerninski, DMD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hebrew University-Hadassah School of Dental Medicine
name: Sharon Elad, DMD MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mizrahi B, Golenser J, Wolnerman JS, Domb AJ. Adhesive tablet effective for treating canker sores in humans. J Pharm Sci. 2004 Dec;93(12):2927-35. doi: 10.1002/jps.20193.
Clinical trial NCT03990623: CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization
Official title: To Evaluate Perfusion Changes to the Liver Following Pre-Operative Portal Vein Embolization for Patients With Liver Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Liver and Intrahepatic Bile Duct Carcinoma
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2019-06-19
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This trial studies the use of computed tomography (CT) perfusion scans in detecting changes in blood flow to the liver after portal vein embolization in patients with liver cancer. CT perfusion scans use a standard contrast drug given by vein to measure blood flow to the liver. CT perfusion scans may predict the rate and amount of growth of new, healthy tissue on one side of the liver after a portal vein embolization and detect change to the size of the liver tumor as result of the procedure.

Detailed description: PRIMARY OBJECTIVES:

I. To assess whether perfusion changes to the liver following portal vein embolization (PVE) correlate with hypertrophy of the future liver remnant (FLR).

SECONDARY OBJECTIVES:

I. To assess perfusion changes to liver tumors following PVE. II. To assess whether PVE may affect tumor growth.

OUTLINE:

Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.

Eligibility criteria: Inclusion Criteria:

* Patients planned to undergo major liver resection for cancer who need PVE to increase the size of the FLR prior to surgery.
* Patients who are able to understand and give consent to participate in the study.

Exclusion Criteria:

* Pregnant or nursing.
* Allergy to iodinated contrast which cannot be safely pre-medicated.
* History of severe renal dysfunction (glomerular filtration rate \[GFR\] \< 30 mL/min/1.73 square meters). Patients with a GFR between 30-50 mL/min/1.73 square meters will receive the standard contrast-induced nephropathy prophylaxis at our institution (i.e. N-acetylcysteine and sodium bicarbonate \[150 mEq/L\] in D5W intravenous).

Primary outcomes:
measure: Perfusion changes to the liver following portal vein embolization (PVE)
timeFrame: Baseline up to 6 weeks post PVE
Secondary outcomes:
measure: Changes to tumor cellular proliferation following PVE
timeFrame: Baseline up to 6 weeks post PVE
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Steven Y Huang, MD
role: PRINCIPAL_INVESTIGATOR
References: